SCHEMBL17547431

SCHEMBL17547431

Cn1ccc2c(=O)c(OCc3ccccc3)c3n(c2c1=O)CCN(Cc1ccc(F)c(Cl)c1)C3=O

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SCD O00767 1/20 0.38
P2RX7 Q99572 2/20 0.37
SMN1; SMN2 Q16637 3/20 0.36
LMNA P02545 2/20 0.36
KDM4E B2RXH2 1/20 0.36
ALDH1A1 P00352 1/20 0.36
HPGD P15428 1/20 0.36
TSHR P16473 1/20 0.36
HTT P42858 1/20 0.36
HSD17B10 Q99714 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
NCOA3 Q9Y6Q9 1/20 0.36
CLPP Q16740 3/20 0.36
GRM2 Q14416 2/20 0.36
DRD4 P21917 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
KCNH2 Q12809 1/20 0.34
FSCN1 Q16658 1/20 0.34
MCL1 Q07820 1/20 0.34
MAOB P27338 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16185259 0.86 GRM2 (0.36) SCDP2RX7SMN1; SMN2LMNAKDM4E
SCHEMBL16180535 0.78 CLPP (0.37) SCDSMN1; SMN2LMNAKDM4EALDH1A1
SCHEMBL16185298 0.78 LMNA (0.37) SCDSMN1; SMN2LMNAKDM4EALDH1A1
SCHEMBL17536999 0.78 LMNA (0.37) SCDSMN1; SMN2LMNAKDM4EALDH1A1
SCHEMBL16185202 0.78 SCD (0.39) SCDSMN1; SMN2LMNAKDM4EALDH1A1
SCHEMBL16180644 0.78 KCNH2 (0.39) SCDSMN1; SMN2LMNAKDM4EALDH1A1
SCHEMBL16185235 0.78 KCNH2 (0.39) SCDSMN1; SMN2LMNAKDM4EALDH1A1
SCHEMBL16180509 0.78 SCD (0.39) SCDSMN1; SMN2LMNAKDM4EALDH1A1
SCHEMBL16180514 0.77 SCD (0.36) SCDSMN1; SMN2LMNAKDM4EALDH1A1
SCHEMBL16185329 0.77 DRD4 (0.38) SCDSMN1; SMN2LMNAKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9493479-B2 Substituted pyrido[1,2-a]pyrazines as HIV integrase inhibitors MERCK SHARP & DOHME CORP. (US) 2016-11-15 US disclosed
US-9493479-B2 Substituted pyrido[1,2-a]pyrazines as HIV integrase inhibitors MERCK SHARP & DOHME CORP. (US) 2016-11-15 US disclosed
US-20160060272-A1 4-PYRIDONE DERIVATIVE COMPOUNDS AND USES THEREOF AS HIV INTEGRASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2016-03-03 US disclosed
US-20160060272-A1 4-PYRIDONE DERIVATIVE COMPOUNDS AND USES THEREOF AS HIV INTEGRASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2016-03-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160060272-A1 4-PYRIDONE DERIVATIVE COMPOUNDS AND USES THEREOF AS HIV INTEGRASE INHIBITORS PNPO, TYMP, PDXK SCD 2858/4885P2RX7 360/4885SMN1; SMN2 3507/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.